Compare BRBR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRBR | PCRX |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2019 | 2010 |
| Metric | BRBR | PCRX |
|---|---|---|
| Price | $8.33 | $23.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $36.63 | $30.25 |
| AVG Volume (30 Days) | ★ 5.5M | 517.6K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 0.65 | 0.07 |
| Revenue | ★ $2,316,600,000.00 | $541,533,000.00 |
| Revenue This Year | $6.28 | $6.78 |
| Revenue Next Year | $5.81 | $8.54 |
| P/E Ratio | ★ $13.33 | $338.29 |
| Revenue Growth | 16.05 | ★ 26.04 |
| 52 Week Low | $8.40 | $18.80 |
| 52 Week High | $63.52 | $27.64 |
| Indicator | BRBR | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 23.61 | 48.10 |
| Support Level | N/A | $22.06 |
| Resistance Level | $19.23 | $24.20 |
| Average True Range (ATR) | 0.55 | 1.04 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 1.31 | 44.31 |
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.